Novel tau biomarkers phosphorylated at T181, T217 or T231 rise in the initial stages of the preclinical Alzheimer’s continuum when only subtle changes in Aβ pathology are detected

Abstract In Alzheimer’s disease (AD), tau phosphorylation in the brain and its subsequent release into cerebrospinal fluid (CSF) and blood is a dynamic process that changes during disease evolution. The main aim of our study was to characterize the pattern of changes in phosphorylated tau (p‐tau) in...

Full description

Saved in:

Bibliographic Details
Main Authors:	Marc Suárez‐Calvet, Thomas K Karikari, Nicholas J Ashton, Juan Lantero Rodríguez, Marta Milà‐Alomà, Juan Domingo Gispert, Gemma Salvadó, Carolina Minguillon, Karine Fauria, Mahnaz Shekari, Oriol Grau‐Rivera, Eider M Arenaza‐Urquijo, Aleix Sala‐Vila, Gonzalo Sánchez‐Benavides, José Maria González‐de‐Echávarri, Gwendlyn Kollmorgen, Erik Stoops, Eugeen Vanmechelen, Henrik Zetterberg, Kaj Blennow, José Luis Molinuevo, for the ALFA Study, Annabella Beteta, Raffaele Cacciaglia, Alba Cañas, Carme Deulofeu, Irene Cumplido, Ruth Dominguez, Maria Emilio, Carles Falcon, Sherezade Fuentes, Laura Hernandez, Gema Huesa, Jordi Huguet, Paula Marne, Tania Menchón, Grégory Operto, Albina Polo, Sandra Pradas, Anna Soteras, Marc Vilanova, Natalia Vilor‐Tejedor
Format:	Article
Language:	English
Published:	Springer Nature 2020-11-01
Series:	EMBO Molecular Medicine
Subjects:	Alzheimer’s disease biomarker cerebrospinal fluid plasma tau
Online Access:	https://doi.org/10.15252/emmm.202012921
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!

Novel tau biomarkers phosphorylated at T181, T217 or T231 rise in the initial stages of the preclinical Alzheimer’s continuum when only subtle changes in Aβ pathology are detected

Similar Items